Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04530799

Prospective Observational Trial of IAPA

Influenza-associated Pulmonary Aspergillosis (IAPA) in ICU Patients With Severe Influenza: Incidence and Host- and Pathogen Related Risk Factors

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
350 (estimated)
Sponsor
Radboud University Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU patients with severe influenza.

Detailed description

Invasive pulmonary aspergillosis was shown to be a complication of severe influenza infections in immunocompromised patients as well as in immunocompetent patients and is associated with a high mortality. Antifungal prophylaxis might prevent influenza-associated pulmonary aspergillosis (IAPA) and thus might improve the outcome in patients with severe influenza. However, clinical related risk factors should be identified to assess whether a patient will benefit from antifungal prophylaxis. This prospective multi-center observational study will assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients in 12 ICUs in The Netherlands, Belgium and France over 4 influenza seasons. The secondary objective of this study is to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU patients with severe influenza. Patients aged 18 or older admitted to the intensive care unit (ICU) during the inclusion period due severe influenza without classic risk factors defined by the EORTC will be included.

Conditions

Interventions

TypeNameDescription
OTHERIdentification of biomarkers for IAPA via patient samplingBlood, BAL, microbiome

Timeline

Start date
2022-03-10
Primary completion
2026-04-30
Completion
2026-04-30
First posted
2020-08-28
Last updated
2026-04-01

Locations

12 sites across 3 countries: Belgium, France, Netherlands

Source: ClinicalTrials.gov record NCT04530799. Inclusion in this directory is not an endorsement.